ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2014
Clinical severity of human infections with avian influenza A(H7N9) virus, China, 2013/14.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- High activity levels of avian influenza upwards 2018-2022: A global epidemiological overview of fowl and human infections.One health (Amsterdam, Netherlands) · 2023Article
- Spatial and temporal clusters of avian influenza a (H7N9) virus in humans across five epidemics in mainland China: an epidemiological study of laboratory-confirmed cases.BMC infectious diseases · 2020Article
- Novel Avian Influenza A Virus Infections of Humans.Infectious disease clinics of North America · 2019Review
- The epidemic potential of avian influenza A (H7N9) virus in humans in mainland China: A two-stage risk analysis.PloS one · 2019Article
- Avian influenza A (H7N9) virus infections in humans across five epidemics in mainland China, 2013-2017.Journal of thoracic disease · 2017Article
- A clinical approach to the threat of emerging influenza viruses in the Asia-Pacific region.Respirology (Carlton, Vic.) · 2017Review
- Preliminary Epidemiologic Assessment of Human Infections With Highly Pathogenic Avian Influenza A(H5N6) Virus, China.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Article
- Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013-17: an epidemiological study of laboratory-confirmed case series.The Lancet. Infectious diseases · 2017Article
- Article
- Population seroprevalence of antibody to influenza A(H7N9) virus, Guangzhou, China.BMC infectious diseases · 2016Article
- Avian influenza A(H7N9) and (H5N1) infections among poultry and swine workers and the general population in Beijing, China, 2013-2015.Scientific reports · 2016Article
- Human Infection with Influenza A(H7N9) Virus during 3 Major Epidemic Waves, China, 2013-2015.Emerging infectious diseases · 2016Article
- Differences in the epidemiology and virology of mild, severe and fatal human infections with avian influenza A (H7N9) virus.Archives of virology · 2016Article
- Interventions to reduce zoonotic and pandemic risks from avian influenza in Asia.The Lancet. Infectious diseases · 2016Review
- Two Genetically Similar H9N2 Influenza A Viruses Show Different Pathogenicity in Mice.Frontiers in microbiology · 2016Article
- Association between Interferon Response and Protective Efficacy of NS1-Truncated Mutants as Influenza Vaccine Candidates in Chickens.PloS one · 2016Article
- Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model.Antimicrobial agents and chemotherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 2 countries.
Funding
Abstract
Assessing the severity of emerging infections is challenging because of potential biases in case ascertainment. The first human case of infection with influenza A(H7N9) virus was identified in China in March 2013; since then, the virus has caused two epidemic waves in the country. There were 134 laboratory-confirmed cases detected in the first epidemic wave from January to September 2013. In the second epidemic wave of human infections with avian influenza A(H7N9) virus in China from October 2013 to October 2014, we estimated that the risk of death among hospitalised cases of infection with influenza A(H7N9) virus was 48% (95% credibility interval: 42-54%), slightly higher than the corresponding risk in the first wave. Age-specific risks of death among hospitalised cases were also significantly higher in the second wave. Using data on symptomatic cases identified through national sentinel influenza-like illness surveillance, we estimated that the risk of death among symptomatic cases of infection with influenza A(H7N9) virus was 0.10% (95% credibility interval: 0.029-3.6%), which was similar to previous estimates for the first epidemic wave of human infections with influenza A(H7N9) virus in 2013. An increase in the risk of death among hospitalised cases in the second wave could be real because of changes in the virus, because of seasonal changes in host susceptibility to severe infection, or because of variation in treatment practices between hospitals, while the increase could be artefactual because of changes in ascertainment of cases in different areas at different times.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.